|
Intensive Care Units
|
N02.278.388.493 |
|
|
Enteropeptidase
|
D08.811.277.656.300.760.284 |
|
|
Beneficence
|
K01.752.566.479.830.500 |
|
|
Asbestosis
|
C08.381.483.581.125 |
|
|
Magnetic Iron Oxide Nanoparticles
|
D000082662 |
[Synthesized nanoparticles related to iron oxide crystalline structures with magnetic properties useful for biomedical applications. Examples include hematite, magnetite and maghemite nanoparticles.
] |
|
Contact Lens Solutions
|
D27.720.274.150 |
|
|
HIV Protease
|
D08.811.277.656.074.500.340 |
|
|
Monieziasis
|
C22.674.377.656 |
|
|
Stroke Volume
|
E01.370.370.380.150.700 |
|
|
Cardiac Output
|
E01.370.370.380.150 |
|
|
Receptors, Serotonin, 5-HT2
|
D12.776.543.750.670.800.200 |
|
|
Spasm
|
C23.888.592.608.750 |
|
|
Eclipta
|
B01.650.940.800.575.912.250.100.337 |
|
|
Women's Health
|
N01.400.900 |
|
|
Receptors, Somatostatin
|
D12.776.543.750.750.580.720 |
|
|
Habituation, Psychophysiologic
|
F02.830.422 |
|
|
Twins
|
M01.438.873 |
|
|
Clotrimazole
|
D03.383.129.308.175 |
|
|
Perinatal Mortality
|
N01.224.935.698.489.500 |
|
|
Infant Mortality
|
N01.224.935.698.489 |
|
